# New clinical trials in Latvia: 76 since Nov 2024

Updated November 4, 2026.

76 clinical studies with a site in Latvia were first posted on ClinicalTrials.gov from November 12, 2024 to November 4, 2026; 48 have an industry sponsor and 48 are recruiting or about to. The newest, NCT07915219, was posted on November 4, 2026: A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After... (Boehringer Ingelheim).

## The full list

New clinical trials with a site in Latvia: 76 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/latvia

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 76
- Industry sponsored: 48
- Recruiting or not yet: 48
- Latest posted: November 4, 2026

## Newest trials

The newest 76 of 76, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| October 30, 2026 | NCT07908108 | Cross-cultural Adaptation and Validation of the Localised Scleroderma Quality of Life Instrument (LoSQI) in Juvenile Localised Scleroderma... | Istituto Giannina Gaslini | Observational | Active not recruiting | Scleroderma | 272 | Argentina, Brazil, China, Croatia, Denmark, Egypt, Germany, Greece, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908108) |
| October 15, 2026 | NCT07876232 | Comparison of Surgical Techniques for Anterior Shoulder Instability | Riga Stradins University | Not applicable | Recruiting | Surgeons, Shoulder Instability, Bankart Lesions, Bankart Repair, Dynamic Stability | 60 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876232) |
| October 13, 2026 | NCT07871331 | EyeBreathe: A Mixed Reality Game With Eye Tracking and Breathing Biofeedback for Adolescent Basketball Players | Riga Stradins University | Not applicable | Active not recruiting | Healthy Adolescents | 45 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871331) |
| October 9, 2026 | NCT07869446 | Extended Reality Cognitive and Breathing Training With Eye Tracking for Attention and Stress Regulation in Adolescent Basketball Players | Riga Stradins University | Not applicable | Completed | Healthy Adolescents | 81 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869446) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Palisade Bio | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | Canada, Czechia, France, Georgia, Hungary, Italy, Latvia, Poland, Romania... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| September 18, 2026 | NCT07828509 | A Retrospective Study on Long-Term Technical Complications of Single Metal-Ceramic Crowns With a Supplementary Questionnaire Survey | Riga Stradins University | Observational | Enrolling by invitation | Metal Ceramic Restorations, Gingival Health | 79 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828509) |
| September 11, 2026 | NCT07814976 | Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for Choledocholithiasis | Riga East Clinical University Hospital | Not applicable | Recruiting | Choledocholithiasis, Common Bile Duct Stones | 50 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814976) |
| July 21, 2026 | NCT07716306 | Remotely Supervised Exercise During Chemotherapy in Women With Breast Cancer | Riga Stradins University | Not applicable | Not yet recruiting | Breast Cancer | 60 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716306) |
| June 16, 2026 | NCT07651826 | Immiseal™ Dural Sealant Post-Market Registry Study | Medprin Regenerative Medical Technologies Co., Ltd. | Observational | Recruiting | Dural Defect, Cerebrospinal Fluid Leak, Neurosurgical Procedures | 85 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651826) |
| June 9, 2026 | NCT07634731 | Bilateral RSB vs TEA Epidural Analgesia for Postoperative Pain Control After Open Gastrectomy: A Randomized Controlled Trial | Igors Ivanovs | Not applicable | Completed | Bilateral Rectus Sheath Block, Thoracic Epidural Analgesia | 60 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634731) |
| May 29, 2026 | NCT07614776 | A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular... | Amgen | Phase 3 | Recruiting | Neovascular Age-related Macular Degeneration, nAMD | 304 | Czechia, Hungary, Japan, Latvia, Lithuania, Poland, Slovakia, Spain, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614776) |
| May 28, 2026 | NCT07611461 | The Effect of Fixed Dentures on Periodontal Tissues in Long-term. | Riga Stradins University | Observational | Enrolling by invitation | Gingival Health, Metal Ceramic Restorations | 75 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611461) |
| May 19, 2026 | NCT07596849 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. | argenx | Phase 3 | Recruiting | Graves Disease | 230 | Belgium, Bulgaria, Canada, Denmark, Georgia, Germany, Greece, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596849) |
| April 8, 2026 | NCT07517120 | Home-Based Stroke Rehabilitation Using Enriched Environments (PEER-HOMEcare) | Norwegian School of Sport Sciences | Not applicable | Not yet recruiting | Stroke | 45 | Latvia, Norway, Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517120) |
| April 6, 2026 | NCT07511686 | Metabolic and Mitochondrial Changes in Statin-Induced Myopathy | Riga Stradins University | Observational | Completed | Statin Adverse Reaction, Statin-induced Myopathy | 38 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511686) |
| April 2, 2026 | NCT07507500 | Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Phase 4 | Recruiting | Myocardial Infarction (MI) | 8,100 | Ireland, Latvia, Norway, Poland, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507500) |
| March 31, 2026 | NCT07503964 | The Significance of Laparoscopic Transcystic Papilla Vateri Balloon Dilatation in Patients With Choledocholithiasis. | Riga East Clinical University Hospital | Not applicable | Active not recruiting | Choledocholithiasis, Choledocholithiasis With Cholecystitis | 100 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503964) |
| March 24, 2026 | NCT07491809 | Adhesive Cementation Materials and Techniques in Aesthetic Dentistry | Riga Stradins University | Not applicable | Recruiting | Dental Veneers, Resin Cements, Composite Restoration, Orofacial Esthetic Scale | 60 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491809) |
| March 19, 2026 | NCT07483827 | A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy | eleva GmbH | Phase 1 | Recruiting | C3 Glomerulopathy (C3G), Healthy Adult Participants | 39 | Austria, Belgium, Czechia, France, Greece, Latvia, Lithuania, Netherlands... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483827) |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472517) |
| February 27, 2026 | NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | Phase 2/3 | Recruiting | Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration | 960 | Argentina, Australia, Estonia, Germany, Israel, Latvia, Poland, Puerto Rico... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440225) |
| February 27, 2026 | NCT07439458 | Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity | Riga Stradins University | Not applicable | Recruiting | Acute Exercise, Breast Cancer Cell Lines, Breast Cancer Survivors, Healthy Women, Myokine Response | 40 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439458) |
| February 20, 2026 | NCT07422688 | Optical Coherence Tomography in Acute Vessel Evaluation | Aarhus University Hospital Skejby | Not applicable | Enrolling by invitation | Ischemic Heart Disease, Ischemic Coronary Artery Disease, ACS (Acute Coronary Syndrome) | 3,000 | Belgium, Denmark, Estonia, Finland, Italy, Latvia, New Zealand, Norway, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422688) |
| February 19, 2026 | NCT07419802 | OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study | Pauls Stradins Clinical University Hospital | Observational | Recruiting | Sepsis, Septic Shock, Blood Purification, Hemoadsorption | 29 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419802) |
| February 17, 2026 | NCT07415044 | LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company | Phase 2 | Recruiting | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | 1,431 | Argentina, Brazil, Canada, China, Colombia, Croatia, Czechia, France, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415044) |
| February 6, 2026 | NCT07393009 | BIO\|STREAM.CSP Study | Biotronik SE & Co. KG | Observational | Recruiting | Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices... | 1,000 | Australia, Austria, Czechia, France, Germany, Hungary, Israel, Italy, Latvia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393009) |
| January 22, 2026 | NCT07360834 | Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome | UNICANCER | Not applicable | Not yet recruiting | Lynch Syndrome | 2,000 | Croatia, Czechia, Finland, France, Italy, Latvia, Netherlands, Norway, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07360834) |
| January 6, 2026 | NCT07318597 | Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) | Regeneron Pharmaceuticals | Phase 2 | Recruiting | Pulmonary Arterial Hypertension (PAH) | 99 | Australia, Belgium, France, Germany, Latvia, Poland, South Korea, Spain, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318597) |
| December 26, 2025 | NCT07304921 | Novel Approach to Increase EPA and DHA Levels | Riga Stradins University | Phase 1 | Completed | Lipid Metabolism, Omega-3 Polyunsaturated Fatty Acids, Supplementation | 48 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07304921) |
| December 24, 2025 | NCT07301736 | Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Chiesi Farmaceutici S.p.A. | Phase 2 | Recruiting | Asthma | 780 | Argentina, Bosnia and Herzegovina, Bulgaria, Czechia, Germany, Hungary, Latvia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301736) |
| December 16, 2025 | NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Takeda | Phase 3 | Recruiting | Psoriatic Arthritis | 1,182 | Australia, China, Croatia, Czechia, Estonia, Germany, Hungary, Israel, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286058) |
| December 16, 2025 | NCT07286006 | A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) | Immunovant Sciences GmbH | Phase 2 | Enrolling by invitation | Graves' Disease | 372 | Australia, Bulgaria, Czechia, Georgia, Hungary, Israel, Latvia, Poland, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286006) |
| December 16, 2025 | NCT07285655 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Liquidia Technologies, Inc. | Phase 3 | Recruiting | Pulmonary Hypertension Due to Lung Disease (Disorder) | 344 | Australia, Austria, Belgium, Canada, France, Germany, Italy, Latvia, Portugal... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285655) |
| December 11, 2025 | NCT07276724 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Generate Biomedicines | Phase 3 | Recruiting | Severe Asthma | 786 | Brazil, Bulgaria, Chile, Czechia, Germany, Greece, Hungary, Israel, Latvia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276724) |
| December 9, 2025 | NCT07272031 | Office Massage Effects on HRV and Stress | Riga Stradins University | Not applicable | Recruiting | Occupational Health, Autonomic Nervous System (ANS) Functioning and Mood State, Stress | 140 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272031) |
| December 9, 2025 | NCT07271862 | A Novel Laparoscopic Apical Promontofixation Technique With Simultaneous Perineal Reconstruction for Patients With Symptomatic Pelvic Organ... | Riga East Clinical University Hospital | Not applicable | Active not recruiting | Pelvic Organ Prolapse (POP), Urinary Incontinence , Stress, Urinary Incontinence (UI), Female Sexual Dysfunction (FSD)... | 60 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07271862) |
| December 2, 2025 | NCT07258290 | Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions | Teleflex | Not applicable | Recruiting | Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular... | 1,859 | Latvia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258290) |
| November 28, 2025 | NCT07254117 | The Role of Granulation Tissue in Periodontal Regeneration | Riga Stradins University | Observational | Completed | Periodontal Bone Loss, Periodontitis, Periodontal Disease, Periodontal Diseases, Periodontal Regeneration, Periodontal... | 34 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254117) |
| November 19, 2025 | NCT07235462 | A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a... | Bayer | Observational | Recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2,000 | Austria, Belgium, Croatia, Denmark, Estonia, Finland, Germany, Italy, Latvia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235462) |
| November 6, 2025 | NCT07225504 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 1,275 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225504) |
| October 24, 2025 | NCT07220915 | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Octapharma | Phase 3 | Recruiting | Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections | 360 | Bulgaria, Czechia, Greece, Latvia, Lithuania, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07220915) |
| September 30, 2025 | NCT07199439 | Post-market Clinical Follow-up Plan of StypCel™ Absorbable Hemostat | Medprin Regenerative Medical Technologies Co., Ltd. | Observational | Completed | Neurosurgery | 108 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199439) |
| September 24, 2025 | NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic... | Sanofi | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | Argentina, Belgium, Brazil, Canada, Chile, China, Denmark, Estonia, Finland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190209) |
| September 16, 2025 | NCT07175038 | A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung... | AllRock Bio, Inc. | Phase 2 | Recruiting | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease | 40 | Australia, Canada, France, Germany, Italy, Latvia, Poland, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175038) |
| August 24, 2025 | NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront... | University Hospital, Basel, Switzerland | Not applicable | Recruiting | Breast Cancer | 1,060 | Austria, Canada, Croatia, Germany, Greece, Ireland, Italy, Latvia, Switzerland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140172) |
| August 22, 2025 | NCT07136467 | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis... | AbbVie | Observational | Recruiting | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | Argentina, Canada, Colombia, Czechia, Estonia, France, Germany, Greece, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136467) |
| August 14, 2025 | NCT07122180 | Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy... | MDCECRO LLC | Observational | Enrolling by invitation | Diabetes Mellitus | 72 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07122180) |
| July 29, 2025 | NCT07091682 | Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | Biotronik AG | Not applicable | Active not recruiting | Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease, Acute... | 100 | Germany, Hungary, Italy, Latvia, Poland, Spain, Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07091682) |
| July 15, 2025 | NCT07064759 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 4D Molecular Therapeutics | Phase 3 | Recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 480 | Argentina, Australia, Bulgaria, France, Germany, Hungary, Israel, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064759) |
| July 14, 2025 | NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood... | Boehringer Ingelheim | Phase 3 | Recruiting | Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases | 11,800 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064473) |
| June 12, 2025 | NCT07018323 | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | Immunovant Sciences GmbH | Phase 2 | Recruiting | Graves' Disease | 210 | Australia, Brazil, Bulgaria, Chile, Czechia, Georgia, Greece, Israel, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07018323) |
| June 11, 2025 | NCT07015905 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Venous Thromboembolism (VTE) | 2,000 | Bulgaria, Hungary, Japan, Latvia, Lithuania, Poland, Romania, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015905) |
| May 25, 2025 | NCT06990867 | Optimizing Reperfusion to Improve Outcomes and Neurologic Function | Corxel Pharmaceuticals | Phase 2/3 | Recruiting | Acute Ischemic Stroke | 740 | Belgium, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06990867) |
| May 20, 2025 | NCT06981078 | A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Upstream Bio Inc. | Phase 2 | Active not recruiting | Chronic Obstructive Pulmonary Disease | 666 | Argentina, Bulgaria, Chile, Czechia, Georgia, Germany, Hungary, India, Ireland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06981078) |
| May 15, 2025 | NCT06973291 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | Takeda | Phase 3 | Completed | Plaque Psoriasis | 606 | Bulgaria, Canada, Czechia, France, Japan, Latvia, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06973291) |
| May 11, 2025 | NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 850 | Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966401) |
| May 8, 2025 | NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | Belgium, Canada, Finland, Hungary, Latvia, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963021) |
| May 7, 2025 | NCT06961214 | Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 961 | Argentina, Australia, Austria, Bulgaria, Czechia, Germany, Greece, Israel... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961214) |
| May 6, 2025 | NCT06959329 | Influence of Sensory Stimulation on Sensory Parameters and Motor Function in Children With Developmental Coordination Disorder | The Jerzy Kukuczka Academy of Physical Education in Katowice | Not applicable | Not yet recruiting | Developmental Coordination Disorder | 80 | Latvia, Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06959329) |
| April 16, 2025 | NCT06930625 | A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs | Debiopharm International SA | Phase 3 | Recruiting | Acromegaly | 119 | Austria, Belgium, Brazil, Bulgaria, Denmark, Estonia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930625) |
| April 10, 2025 | NCT06920771 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL... | HAL Allergy | Phase 3 | Completed | House Dust Mite Allergy, House Dust Mite Rhinitis | 691 | Bulgaria, Germany, Latvia, Lithuania, Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920771) |
| April 3, 2025 | NCT06908226 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | Longboard Pharmaceuticals | Phase 3 | Enrolling by invitation | Developmental and Epileptic Encephalopathy | 324 | Australia, Belgium, Brazil, Canada, China, France, Germany, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06908226) |
| March 18, 2025 | NCT06880770 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | Arrowhead Pharmaceuticals | Phase 3 | Recruiting | Severe Hypertriglyceridemia | 288 | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880770) |
| March 18, 2025 | NCT06880744 | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab... | AbbVie | Phase 3 | Active not recruiting | Ulcerative Colitis | 573 | Austria, Bulgaria, Canada, China, Croatia, Czechia, Estonia, Finland, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880744) |
| March 12, 2025 | NCT06872892 | The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | Boehringer Ingelheim | Phase 3 | Recruiting | Bronchiectasis | 1,755 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06872892) |
| March 5, 2025 | NCT06858579 | A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) | Dianthus Therapeutics | Phase 3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 256 | Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858579) |
| February 26, 2025 | NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | Alumis Inc | Phase 3 | Active not recruiting | Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis | 1,680 | Australia, Bulgaria, Canada, Czechia, Estonia, France, Germany, Hungary, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846541) |
| February 25, 2025 | NCT06846138 | Enhancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Formulation: a Gut Microbiome Study | Pauls Stradins Clinical University Hospital | Not applicable | Enrolling by invitation | Diabetes Mellitus Type 2 | 66 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846138) |
| February 12, 2025 | NCT06822790 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Arrowhead Pharmaceuticals | Phase 3 | Active not recruiting | Hypertriglyceridemia | 710 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06822790) |
| January 14, 2025 | NCT06774131 | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | UroGen Pharma Ltd. | Phase 3 | Recruiting | Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | 70 | Bulgaria, Georgia, Hungary, Israel, Latvia, Poland, Romania, Spain, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06774131) |
| December 19, 2024 | NCT06742190 | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy | argenx | Phase 3 | Active not recruiting | Multifocal Motor Neuropathy (MMN), MMN | 154 | Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06742190) |
| December 16, 2024 | NCT06734962 | Evaluation of Bone Regeneration After Apical Surgery Using Advanced Platelet-rich Fibrin: Utilization of Ultrasound for the Assessment of... | Riga Stradins University | Phase 2 | Active not recruiting | Periapical Lesions | 44 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06734962) |
| December 10, 2024 | NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and... | Immutep S.A.S. | Phase 3 | Active not recruiting | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 756 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06726265) |
| December 5, 2024 | NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | Longboard Pharmaceuticals | Phase 3 | Active not recruiting | Developmental and Epileptic Encephalopathy | 367 | Australia, Belgium, Brazil, Canada, China, France, Germany, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06719141) |
| November 12, 2024 | NCT06684769 | A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations | Riga Stradins University | Not applicable | Recruiting | Periodontitis, Adult, Furcation Defects, Furcation of Root of Tooth, Periodontitis Complex | 40 | Latvia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06684769) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Riga Stradins University | 14 | October 15, 2026 |
| Boehringer Ingelheim | 4 | November 4, 2026 |
| Riga East Clinical University Hospital | 3 | September 11, 2026 |
| Medprin Regenerative Medical Technologies Co., Ltd. | 2 | June 16, 2026 |
| argenx | 2 | May 19, 2026 |
| Pauls Stradins Clinical University Hospital | 2 | February 19, 2026 |
| Regeneron Pharmaceuticals | 2 | January 6, 2026 |
| Takeda | 2 | December 16, 2025 |
| Immunovant Sciences GmbH | 2 | December 16, 2025 |
| AbbVie | 2 | August 22, 2025 |
| Neurocrine Biosciences | 2 | May 11, 2025 |
| Longboard Pharmaceuticals | 2 | April 3, 2025 |
| Arrowhead Pharmaceuticals | 2 | March 18, 2025 |
| Istituto Giannina Gaslini | 1 | October 30, 2026 |
| Palisade Bio | 1 | September 29, 2026 |
| Igors Ivanovs | 1 | June 9, 2026 |
| Amgen | 1 | May 29, 2026 |
| Norwegian School of Sport Sciences | 1 | April 8, 2026 |
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1 | April 2, 2026 |
| eleva GmbH | 1 | March 19, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Acute Coronary Syndrome](https://specstream.ai/data/clinical-trials/condition/acute-coronary-syndrome) | 4 | April 2, 2026 |
| [Colitis, Ulcerative](https://specstream.ai/data/clinical-trials/condition/colitis-ulcerative) | 3 | September 29, 2026 |
| Graves Disease | 3 | May 19, 2026 |
| Myocardial Ischemia | 3 | February 20, 2026 |
| [Hypertension, Pulmonary](https://specstream.ai/data/clinical-trials/condition/hypertension-pulmonary) | 3 | January 6, 2026 |
| [Pulmonary Disease, Chronic Obstructive](https://specstream.ai/data/clinical-trials/condition/pulmonary-disease-chronic-obstructive) | 3 | September 24, 2025 |
| Bronchiectasis | 2 | November 4, 2026 |
| Choledocholithiasis | 2 | September 11, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 2 | July 21, 2026 |
| [Hemorrhage](https://specstream.ai/data/clinical-trials/condition/hemorrhage) | 2 | April 2, 2026 |
| Macular Degeneration | 2 | February 27, 2026 |
| Wet Macular Degeneration | 2 | February 27, 2026 |
| [Heart Failure](https://specstream.ai/data/clinical-trials/condition/heart-failure) | 2 | February 6, 2026 |
| Pulmonary Arterial Hypertension | 2 | January 6, 2026 |
| [Asthma](https://specstream.ai/data/clinical-trials/condition/asthma) | 2 | December 24, 2025 |
| [Lung Diseases, Interstitial](https://specstream.ai/data/clinical-trials/condition/lung-diseases-interstitial) | 2 | December 16, 2025 |
| [Cardiovascular Diseases](https://specstream.ai/data/clinical-trials/condition/cardiovascular-diseases) | 2 | December 2, 2025 |
| [Coronary Artery Disease](https://specstream.ai/data/clinical-trials/condition/coronary-artery-disease) | 2 | December 2, 2025 |
| Angina Pectoris | 2 | December 2, 2025 |
| [Diabetes Mellitus](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus) | 2 | August 14, 2025 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 2 | July 14, 2025 |
| [Depressive Disorder, Major](https://specstream.ai/data/clinical-trials/condition/depressive-disorder-major) | 2 | May 11, 2025 |
| [Depression](https://specstream.ai/data/clinical-trials/condition/depression) | 2 | May 11, 2025 |
| Seizures | 2 | April 3, 2025 |
| [Epilepsy](https://specstream.ai/data/clinical-trials/condition/epilepsy) | 2 | April 3, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 30 | November 4, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 20 | October 15, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 12 | October 30, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 9 | September 29, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 2 | March 19, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | February 27, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | April 2, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).